Ensign Peak Advisors
SAGE

Ensign Peak Advisors’s Sage Therapeutics SAGE Stock Holding History

Ensign Peak Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-44,021
Closed -$239K – 1720
2024
Q4 		$239K Buy
44,021
+1,300
+3% +$7.95K ﹤0.01% 1690
2024
Q3 		$308K Buy
42,721
+13,200
+45% +$121K ﹤0.01% 1672
2024
Q2 		$321K Hold
29,521
– – ﹤0.01% 1675
2024
Q1 		$553K Sell
29,521
-1,489
-5% -$34.3K ﹤0.01% 1598
2023
Q4 		$672K Hold
31,010
– – ﹤0.01% 1583
2023
Q3 		$638K Hold
31,010
– – ﹤0.01% 1501
2023
Q2 		$1.46M Hold
31,010
– – ﹤0.01% 1003
2023
Q1 		$1.3M Hold
31,010
– – ﹤0.01% 1033
2022
Q4 		$1.18M Buy
31,010
+15,950
+106% +$609K ﹤0.01% 1036
2022
Q3 		$590K Buy
15,060
+7,120
+90% +$275K ﹤0.01% 1368
2022
Q2 		$256K Hold
7,940
– – ﹤0.01% 1721
2022
Q1 		$263K Hold
7,940
– – ﹤0.01% 1795
2021
Q4 		$338K Sell
7,940
-13,627
-63% -$571K ﹤0.01% 1773
2021
Q3 		$956K Sell
21,567
-7,745
-26% -$355K ﹤0.01% 1452
2021
Q2 		$1.67M Buy
29,312
+8,752
+43% +$619K ﹤0.01% 1225
2021
Q1 		$1.54M Sell
20,560
-5,490
-21% -$450K ﹤0.01% 1234
2020
Q4 		$2.25M Hold
26,050
– – 0.01% 988
2020
Q3 		$1.59M Buy
26,050
+13,066
+101% +$662K ﹤0.01% 1097
2020
Q2 		$539K Sell
12,984
-2,115
-14% -$76.8K ﹤0.01% 1447
2020
Q1 		$433K Sell
15,099
-4,257
-22% -$247K ﹤0.01% 1425
2019
Q4 		$1.4M Buy
+19,356
New +$2.38M ﹤0.01% 1207

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Ensign Peak Advisors's SAGE Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 44,021 shares — an estimated $239K sold.

Ensign Peak Advisors first reported a position in SAGE in Q4 2019 and held it in 21 quarters. The position peaked at $2.25M in Q4 2020. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Ensign Peak Advisors reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 44,021 Sage Therapeutics shares in Q1 2025, an estimated $239K.
  • Ensign Peak Advisors first reported a position in Sage Therapeutics in Q4 2019 and held it in 21 quarters.
  • Ensign Peak Advisors's Sage Therapeutics position peaked at $2.25M in Q4 2020.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.